X4 Pharmaceuticals closed a public offering of 52,844,000 shares of common stock, raising approximately $155.3 million. The total shares outstanding after the offering is 79,214,708. The offering was managed by Leerink Partners, Stifel, and Guggenheim Securities. X4 is focused on developing therapies for rare hematology diseases and is currently marketing mavorixafor in the U.S. as XOLREMDI®. The company is also conducting a Phase 3 clinical trial for additional uses of mavorixafor. X4 Pharmaceuticals is headquartered in Boston, Massachusetts. For more information, contact [email protected].

Read more at GlobeNewswire: X4 Pharmaceuticals Announces Closing of Public Offering and